Continued investment in research and development
First written in FY2017-Q1. 14 of 32 entries say "Restated". Latest entry: FY2026.
56 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Total research and development expenses for the consolidated fiscal year amounted to ¥2,898 million. To accelerate the development of these new technologies and products, the Company constructed a new research building in the Beppu district, which was completed in June 2026.」
Research and development expenses of ¥2,898 million were recorded, and the new research building in the Beppu district was completed in June 2026. In addition, development has reached a more concrete stage for products that further reduce paper diaper materials by approximately 20%, semiconductor insulating film materials, additives for LIB electrolytes, and CO2 separation and recovery technologies, among others. - FY2026-H1Research and development expenses increased year on yearAnnual report
「Total R&D expenses for the cumulative consolidated interim period amounted to ¥1,421 million.」
R&D expenses increased from ¥1,344 million in the same period of the previous year to ¥1,421 million, and R&D investment continued. - FY2025-H1R&D expenses decreased year on yearAnnual report
「Total R&D expenses for the cumulative consolidated interim period amounted to ¥1,344 million.」
R&D investment continued, but R&D expenses declined from ¥1,397 million in the same period of the previous year to ¥1,344 million. - FY2024-Q3Research and development expenses increased year on yearAnnual report
「Total R&D expenses for the cumulative consolidated third quarter amounted to ¥2,047 million.」
R&D spending continued, increasing from ¥1,901 million in the same period of the previous year to ¥2,047 million for the cumulative third quarter. - FY2024-Q2Research and development expenses increased year on yearAnnual report
「Total R&D expenses for the cumulative consolidated second quarter amounted to ¥1,397 million.」
R&D expenses increased from ¥1,290 million in the same period of the previous year to ¥1,397 million, and R&D investment continued. - FY2024-Q1Research and development expenses increased year on yearAnnual report
「Total R&D expenses for the cumulative consolidated first quarter amounted to ¥725 million.」
R&D expenses increased from ¥645 million in the same period of the previous year to ¥725 million, and R&D investment continued. - FY2023AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year amounted to ¥2,691 million.」
R&D investment continued, and R&D expenses increased from ¥2,628 million in the previous fiscal year to ¥2,691 million. The details of the research, including superabsorbent polymers, next-generation semiconductor materials, LiB materials and GHG reduction technologies, have also been specified. - FY2023-Q3Research and development expenses increased year on yearAnnual report
「Total R&D expenses for the cumulative consolidated third quarter amounted to ¥2,009 million.」
R&D spending continued, increasing from ¥1,901 million in the same period of the previous year to ¥2,009 million for the cumulative third quarter. - FY2023-Q1R&D expenses decreased year on yearAnnual report
「Total R&D expenses for the cumulative consolidated first quarter amounted to ¥645 million.」
R&D spending continued, but declined from ¥700 million in the same period of the previous year to ¥645 million. - FY2022R&D expenses declined year on yearAnnual report
「In FY2022, the final year of the current three-year medium-term management plan, the company is pursuing R&D activities after identifying the functions and other capabilities required in the growth areas defined for its 3 existing businesses, with the aim of achieving its targets and laying the groundwork for growth from the following fiscal year onward. Total R&D expenses for the consolidated fiscal year amounted to ¥2,628 million」
R&D activities continued in the final year of the medium-term management plan, while R&D expenses declined from ¥2,909 million in the previous fiscal year to ¥2,628 million. - FY2022-Q3R&D expenses decreased year on yearAnnual report
「Total R&D expenses for the cumulative consolidated third quarter amounted to ¥1,901 million.」
R&D spending continued, but declined from ¥2,161 million in the same period of the previous year to ¥1,901 million. - FY2022-Q2RestatedAnnual report
「Total R&D expenses for the cumulative consolidated second quarter amounted to ¥1,364 million.」
R&D spending continued, but declined from ¥1,484 million in the same period of the previous year to ¥1,364 million. - FY2022-Q1R&D expenses decreased year on yearAnnual report
「Total R&D expenses for the cumulative consolidated first quarter amounted to ¥653 million.」
R&D investment continued, but R&D expenses declined from ¥700 million in the same period of the previous year to ¥653 million. - FY2021R&D expenses declined while R&D management functions were strengthenedAnnual report
「Under the medium-term management plan for FY2020 through FY2022, the company is strengthening R&D aimed at transforming its business structure so that all 3 businesses drive growth, as well as supporting future growth. In addition to reorganizing its research institutes in April 2019 to improve the efficiency and speed of R&D, the company strengthened its company-wide R&D management functions in July 2020, selecting development themes and allocating research resources effectively from a company-wide perspective. Total R&D expenses for the consolidated fiscal year amounted to ¥2,909 million.」
R&D expenses declined from ¥3,200 million in the previous fiscal year to ¥2,909 million, despite strengthened R&D management functions and resource allocation. - FY2021-Q3R&D expenses decreased year on yearAnnual report
「Total R&D expenses for the cumulative consolidated third quarter amounted to ¥2,161 million.」
R&D investment continued, but R&D expenses for the cumulative third quarter declined from ¥2,368 million in the same period of the previous year to ¥2,161 million. - FY2021-Q2RestatedAnnual report
「Total R&D expenses for the cumulative consolidated second quarter amounted to ¥1,484 million.」
R&D expenses were also recorded for the cumulative second quarter, with the continued investment in R&D disclosed by amount. - FY2021-Q1RestatedAnnual report
「Total R&D expenses for the cumulative consolidated first quarter amounted to ¥700 million.」
R&D expenses were also recorded in the first quarter, with the continued investment in R&D disclosed by amount. - FY2020AdvancedAnnual report
「To improve the efficiency and speed of its R&D activities, the company integrated the research institutes previously assigned to 3 business divisions into 2 institutes, the Development Research Institute and the Production Technology Research Institute. It selects development themes and allocates research resources from a company-wide perspective. Total R&D expenses for the consolidated fiscal year amounted to ¥3,200 million.」
The company consolidated its research institutes from a 3-site structure into a 2-institute structure comprising the Development Research Institute and the Production Technology Research Institute, and recorded ¥3,200 million in R&D expenses. - FY2020-Q3RestatedAnnual report
「Total R&D expenses for the cumulative consolidated third quarter amounted to ¥2,368 million.」
R&D expenses were also recorded for the cumulative third quarter, with the continued investment in R&D disclosed by amount. - FY2020-Q2RestatedAnnual report
「Total R&D expenses for the cumulative consolidated second quarter amounted to ¥1,607 million.」
The company recorded ¥1,607 million in R&D expenses for the cumulative second quarter and disclosed the continued investment in R&D. - FY2020-Q1RestatedAnnual report
「Total R&D expenses for the cumulative consolidated first quarter amounted to ¥795 million.」
R&D expenses were also recorded in the first quarter, with the continued investment in R&D disclosed by amount. - FY2019-Q3RestatedAnnual report
「Total R&D expenses for the cumulative consolidated third quarter amounted to ¥2,042 million.」
R&D expenses were also recorded for the cumulative consolidated third quarter, with the continued investment in R&D disclosed by amount. - FY2019-Q2RestatedAnnual report
「Total R&D expenses for the cumulative consolidated second quarter amounted to ¥1,377 million.」
R&D expenses were also recorded for the cumulative consolidated second quarter, with the continued investment in R&D disclosed by amount. - FY2019-Q1RestatedAnnual report
「Total R&D expenses for the cumulative consolidated first quarter amounted to ¥686 million.」
R&D expenses were also recorded for the cumulative first quarter, with the continued investment in R&D disclosed by amount. - FY2018AdvancedAnnual report
「In the third year of the medium- to long-term management plan (SEIKA Grand Design 2025 “URUOI”), the company will steadily advance and accelerate its R&D activities toward its vision for 2025. It will actively promote the development of new products based on its core technologies in the medical and lifestyle-related, environmental and energy, and electronics fields, which it has positioned as business domains for creating new businesses. Total R&D expenses for the consolidated fiscal year amounted to ¥2,733 million.」
In the third year of the medium- to long-term plan, the company advanced and accelerated its R&D activities and recorded ¥2,733 million in R&D expenses. The development and sale of battery materials, specialty optical materials, new thickeners, high-purity material gases and other products were also cited as achievements. - FY2018-Q3RestatedAnnual report
「Total R&D expenses for the cumulative consolidated third quarter amounted to ¥1,927 million.」
R&D expenses were also recorded for the cumulative third quarter, with the continued investment in R&D disclosed by amount. - FY2018-Q2RestatedAnnual report
「Total R&D expenses for the cumulative consolidated second quarter amounted to ¥1,334 million.」
R&D expenses were also recorded for the cumulative second quarter, with the continued investment in R&D disclosed by amount. - FY2018-Q1RestatedAnnual report
「Total R&D expenses for the cumulative consolidated first quarter amounted to ¥649 million.」
R&D expenses were also recorded for the cumulative first quarter, with the continued investment in R&D disclosed by amount. - FY2017AdvancedAnnual report
「As part of these initiatives, the company will invest approximately 4% of consolidated net sales in total R&D expenses and make investments of approximately ¥80 billion, aiming to achieve net sales of ¥170 billion, operating profit of ¥20 billion, an operating margin of 12%, and ROE of more than 12% as targets for the final year, FY2025.」
The company disclosed a medium- to long-term policy of recording ¥2,395 million in R&D expenses for the full year while investing approximately 4% of net sales in total R&D expenses. - FY2017-Q3RestatedAnnual report
「Total R&D expenses for the cumulative consolidated third quarter amounted to ¥1,822 million.」
R&D expenses were also recorded for the cumulative third quarter, with the continued investment in R&D disclosed by amount. - FY2017-Q2RestatedAnnual report
「Total R&D expenses for the cumulative consolidated second quarter amounted to ¥1,232 million.」
The company disclosed continued R&D spending as an amount for the cumulative second quarter. - FY2017-Q1First statedAnnual report
「Total R&D expenses for the cumulative consolidated first quarter amounted to ¥592 million.」
R&D expenses for the cumulative first quarter were disclosed by amount.